Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans

Molecular Biology and Evolution

Volumn 31, Issue 2, 2014, Pages 397-409

  Depledge, Daniel P ^a   Kundu, Samit ^a   Jensen, Nancy J ^b   Gray, Eleanor R ^a   Jones, Meleri ^a   Steinberg, Sharon ^c   Gershon, Anne ^c   Kinchington, Paul R ^d   Schmid, D Scott ^b   Balloux, Francois ^e   Nichols, Richard A ^f   Breuer, Judith ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

alphaherpesvirus; pathogenesis; viral evolution

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ALLELE; ARTICLE; CHICKENPOX; CONTROLLED STUDY; EUKARYOTE EVOLUTION; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HAPLOTYPE; HERPES ZOSTER; HUMAN; HYBRIDIZATION; MONOPHYLY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; SPECIES; VACCINATION; VACCINE PRODUCTION; VARICELLA ZOSTER VIRUS; VESICULAR RASH; VIRUS ATTENUATION; VIRUS GENOME; VIRUS LATENCY; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS RECOMBINATION; WILD TYPE;

ALPHAHERPESVIRUS; PATHOGENESIS; VIRAL EVOLUTION;

ALLELES; EVOLUTION, MOLECULAR; EXANTHEMA; GENOME, VIRAL; GENOTYPE; HERPESVIRUS 3, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION RATE; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; SELECTION, GENETIC; SKIN; VIRAL VACCINES;

EID: 84893118922     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/mst210     Document Type: Article

References (62)

1. Arvin AM. 2001. Varicella-zoster virus: molecular virology and virus-host interactions. Curr Opin Microbiol. 4:442-449.
2. Balding DJ. 2003. Likelihood-based inference for genetic correlation coefficients. Theor Popul Biol. 63:221-230.
3. Banovic T, Yanilla M, Simmons R, Robertson I, SchroderWA, Raffelt NC, Wilson YA, Hill GR, Hogan P, Nourse CB. 2011. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis. 204:1893-1901.
4. Barrett-Muir W, Scott FT, Aaby P, Scott FT, Aaby P, John J, Matondo P, Chaudhry QL, Siqueira M, Poulsen A, Yaminishi K, Breuer J. 2003. Genetic variation of varicella-zoster virus: evidence for geographical separation of strains. J Med Virol. 70(1 Suppl):S42-S47.
5. Breuer J, Schmid DS. 2008. Vaccine Oka variants and sequence variability in vaccine-related skin lesions. J Infect Dis. 197(Suppl):S54-S57.
6. Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, Seward JF. 2008. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis. 197(2 Suppl):S170-S177.
7. Chen JJ, Gershon AA, Li ZS, Lungu O, Gershon MD. 2003. Latent and lytic infection of isolated guinea pig enteric ganglia by varicella zoster virus. J Med Virol. 70(1 Suppl):S71-S78.
8. Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, Seward JF. 2009. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 28:954-959.
9. Cohen J. 1988. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates.
10. Cohen JI. 2007. Varicella-zoster vaccine virus: evolution in action. Proc Natl Acad Sci USA. 104:7-8.
11. Cohrs R, Gilden D, Gomi Y. 2006. Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of varicella-zoster virus. J Virol. 80:2076-2082.
12. Davison AJ, Scott JE. 1986. The complete DNA sequence of varicellazoster virus. J Gen Virol. 67:1759-1816.
13. Depledge DP, Palser AL, Watson SJ, Lai IY, Gray ER, Grant P, Kanda RK, Leproust E, Kellam P, Breuer J. 2011. Specific capture and wholegenome sequencing of viruses from clinical samples. PLoS One 6: e27805.
14. Drummond A, Suchard M, Xie D, Rambaut A. 2012. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol. 29: 1969-1973.
15. Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. 2002. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. Society 76:11447-11459.
16. Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J. 2010. Safety profile of live varicella virus vaccine (Oka/Merck): fiveyear results of the European varicella zoster virus identification program (EU VZVIP). Vaccine 28:5878-5882.
17. Heckerman D, Kadie C, Listgarten J. 2006. Leveraging information across HLA alleles/supertypes improves epitope prediction. J Comput Biol. 14:736-746.
18. Hochberg Y, Benjamini Y. 1990. More powerful procedures for multiple significance testing. Stat Med. 9:811-818.
19. Hondo R, Yogo Y. 1988. Strain variation of R5 direct repeats in the righthand portion of the long unique segment of varicella-zoster virus DNA. J Virol. 62:2916-2921.
20. Kanda RK, Quinlivan ML, Gershon AA, Nichols RA, Breuer J. 2011. Population diversity in batches of the varicella Oka vaccine. Vaccine 29:3293-3298.
21. Katoh K. 2002. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30: 3059-3066.
22. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. 2012. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22:568-576.
23. Kramer JM, LaRussa P, Tsai WC, Carney P, Leber SM, Gahagan S, Steinberg S, Blackwood RA. 2001. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 108:e39-e39.
24. Larussa P, Steinberg S, Arvin A, Dwyer D, Burgess M, MenegusM, Rekrut K, Yamanishi K, Gershon A. 1998. Polymerase chain reaction and restriction fragment length polymorphism analysis of varicellazoster virus isolates from the United States and other parts of the world. J Infect Dis. 178:64-66.
25. Lee S, Markham P, Coppo M. 2012. Attenuated vaccines can recombine to form virulent field viruses. Science 337:2012.
26. Levin MJ, DeBiasi RL, Bostik V, Schmid DS. 2008. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis. 198: 1444-1447.
27. Levy O, Orange JS, Hibberd P, et al. (12 co-authors). 2003. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis. 188:948-953.
28. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754-1760.
29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078-2079.
30. Loman NJ, Misra R V, Dallman TJ, Constantinidou C, Gharbia SE,Wain J, Pallen MJ. 2012. Performance comparison of benchtop highthroughput sequencing platforms. Nat Biotechnol. 30:434-439.
31. Loparev VN, Rubtcova E, Seward JF, Levin MJ, Schmid DS. 2007. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis. 195:502-510.
32. Lynch JM, Kenyon TK, Grose C, Hay J, Ruyechan WT. 2002. Physical and functional interaction between the varicella zoster virus IE63 and IE62 proteins. Virology 302:71-82.
33. MacNamara A, Kadolsky U. 2009. T-cell epitope prediction: rescaling can mask biological variation between MHC molecules. PLoS Comput Biol. 5:e1000327.
34. Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P. 2010. RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics 26(19):2462-2463.
35. Minoche AE, Dohm JC, Himmelbauer H. 2011. Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol. 12:R112.
36. Moffat J, Zerboni L, Kinchington P. 1998. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol. 72:965-974.
37. Parker J, Rambaut A, Pybus OG. 2008. Correlating viral phenotypes with phylogeny: accounting for phylogenetic uncertainty. Infect Genet Evol. 8:239-246.
38. Parker SP, Quinlivan M, Taha Y, Breuer J. 2006. Genotyping of varicellazoster virus and the discrimination of Oka vaccine strains by TaqMan real-time PCR. J Clin Microbiol. 44:3911-3914.
39. Peters GA, Tyler SD, Carpenter JE, Jackson W, Mori Y, Arvin AM, Grose C. 2012. The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation. J Virol. 86:10695-10703.
40. Peters GA, Tyler SD, Grose C, Severini A, Gray MJ, Upton C, Tipples GA. 2006. A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades. J Virol. 80:9850-9860.
41. Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD. 2006. GARD: a genetic algorithm for recombination detection. Bioinformatics 22(24):3096-3098.
42. Posada D. 2008. Model Test: phylogenetic model averaging. Mol Biol Evol. 25:1253-1256.
43. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y. 2012. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13:341.
44. Quinlivan M, Breuer J, Schmid DS. 2011. Molecular studies of the Oka varicella vaccine. Expert Rev Vaccines. 10:1321-1336.
45. Quinlivan MA, Gershon AA, Nichols RA, La Russa P, Steinberg SP, Breuer J. 2006. Vaccine Oka varicella-zoster virus genotypes are monomorphic in single vesicles and polymorphic in respiratory tract secretions. J Infect Dis. 193:927-930.
46. Quinlivan ML, Gershon AA, Al Bassam MM, Steinberg SP, LaRussa P, Nichols RA, Breuer J. 2007. Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc Natl Acad Sci USA. 104:208-212.
47. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. 2004. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis. 190:793-796.
48. Rentier B, Gershon AA. 2004. Consensus: varicella vaccination of healthy children. Pediatr Infect Dis J. 23:379-389.
49. Sengupta N, Taha Y, Scott FT, Leedham-Green ME, Quinlivan M, Breuer J. 2007. Varicella-zoster-virus genotypes in East London: a prospective study in patients with herpes zoster. J Infect Dis. 196:1014-1020.
50. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA. 2000. The postmarketing safety profile of varicella vaccine. Vaccine 19:916-923.
51. Slatkin M, Maddison WP. 1989. A cladistic measure of gene flow measured from the phylogenies of alleles. Genetics 123:603-613.
52. Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A. 1975. Development of a live attenuated varicella vaccine. Biken J. 18:25-33.
53. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 28:2731-2739.
54. Thiele S, Borschewski A, Küchler J, Bieberbach M, Voigt S, Ehlers B. 2011. Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions. Clin Vaccine Immunol. 18: 1058-1066.
55. Tillieux SL, Halsey WS, Thomas ES, Voycik JJ, Sathe GM, Vassilev V. 2008. Complete DNA sequences of two oka strain varicella-zoster virus genomes. J Virol. 82:11023-11044.
56. Tsolia M, Gershon AA, Steinberg SP, Gelb L. 1990. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr. 116:184-189.
57. Tyler SD, Peters GA, Grose C, Severini A, Gray MJ, Upton C, Tipples GA. 2007. Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology 359:447-458.
58. Wang TH, Donaldson YK, Brettle RP, Bell JE, Simmonds P. 2001. Identification of shared populations of Human immunodeficiency Virus Type 1 infectingmicroglia and tissue macrophages outside the central nervous system. J Virol. 75:11686-11699.
59. Watson SJ,Welkers MR, Depledge DP, Coulter E, Breuer JM, de Jong MD, Kellam P. 2013. Viral population analysis and minority-variant detection using short read next-generation sequencing. Philos Trans R Soc Lond B Biol Sci. 368:20120205.
60. Zerboni L, Hinchliffe S, Sommer MH, et al. (11 co-authors). 2005. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 332:337-346.
61. Zhang Z, Selariu A, Warden C, Huang G, Huang Y, Zaccheus O, Cheng T, Xia N, Zhu H. 2010. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS Pathog. 6:e1000971.
62. Zhu LA, Weller SK. 1992. The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase-primase, are essential for its function. J Virol. 66: 469-479.